Cargando…
Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
INTRODUCTION: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019425/ https://www.ncbi.nlm.nih.gov/pubmed/27660456 http://dx.doi.org/10.2147/TCRM.S107398 |
_version_ | 1782453055121260544 |
---|---|
author | Moghaddam, Arash Graeser, Viola Westhauser, Fabian Dapunt, Ulrike Kamradt, Till Woerner, Stefan M Schmidmaier, Gerhard |
author_facet | Moghaddam, Arash Graeser, Viola Westhauser, Fabian Dapunt, Ulrike Kamradt, Till Woerner, Stefan M Schmidmaier, Gerhard |
author_sort | Moghaddam, Arash |
collection | PubMed |
description | INTRODUCTION: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic index and serious side effects; it is potentially nephrotoxic as well as ototoxic. It is not yet known if relevant gentamicin concentrations are released into the systemic circulation after implantation of gentamicin-coated nails. In order to evaluate the patients’ risks profiles and increase patient safety, we measured gentamicin levels in pre- and postoperative serum samples of patients undergoing implantation of ETN PROtect. METHODS: Twenty-five patients who received ETN PROtect between March 2012 and August 2014 were included in this study. Collection of blood samples occurred before the operation, at weeks 1–4, 3 and 6 months, and up to 1 year after the implantation. Measurement of gentamicin levels in serum samples was performed at the central laboratory of Heidelberg University Hospital. Additionally, laboratory parameters, C-reactive protein, leukocyte number, urea and creatinine concentrations were analyzed in routine controls before and after operating and assessed for systemic side effects. RESULTS: Over the course of this prospective observational study, we were able to determine that gentamicin-coated nails do not release gentamicin into the systemic circulation above the lowest detectable level of 0.2 mg/dL. There were slight increases in the mean inflammation and renal retention markers, but no gentamicin-associated side effects could be linked to implantation. Furthermore, no allergic reactions could be detected during our study. CONCLUSION: Our findings suggest that there is no relevant release of gentamicin into the systemic circulation causing a systemic effect, and serious side effects due to gentamicin-coated tibia nails should not be feared. Postoperative monitoring of renal function does not seem necessary because of the implantation of ETN PROtect. |
format | Online Article Text |
id | pubmed-5019425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50194252016-09-22 Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? Moghaddam, Arash Graeser, Viola Westhauser, Fabian Dapunt, Ulrike Kamradt, Till Woerner, Stefan M Schmidmaier, Gerhard Ther Clin Risk Manag Original Research INTRODUCTION: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic index and serious side effects; it is potentially nephrotoxic as well as ototoxic. It is not yet known if relevant gentamicin concentrations are released into the systemic circulation after implantation of gentamicin-coated nails. In order to evaluate the patients’ risks profiles and increase patient safety, we measured gentamicin levels in pre- and postoperative serum samples of patients undergoing implantation of ETN PROtect. METHODS: Twenty-five patients who received ETN PROtect between March 2012 and August 2014 were included in this study. Collection of blood samples occurred before the operation, at weeks 1–4, 3 and 6 months, and up to 1 year after the implantation. Measurement of gentamicin levels in serum samples was performed at the central laboratory of Heidelberg University Hospital. Additionally, laboratory parameters, C-reactive protein, leukocyte number, urea and creatinine concentrations were analyzed in routine controls before and after operating and assessed for systemic side effects. RESULTS: Over the course of this prospective observational study, we were able to determine that gentamicin-coated nails do not release gentamicin into the systemic circulation above the lowest detectable level of 0.2 mg/dL. There were slight increases in the mean inflammation and renal retention markers, but no gentamicin-associated side effects could be linked to implantation. Furthermore, no allergic reactions could be detected during our study. CONCLUSION: Our findings suggest that there is no relevant release of gentamicin into the systemic circulation causing a systemic effect, and serious side effects due to gentamicin-coated tibia nails should not be feared. Postoperative monitoring of renal function does not seem necessary because of the implantation of ETN PROtect. Dove Medical Press 2016-09-07 /pmc/articles/PMC5019425/ /pubmed/27660456 http://dx.doi.org/10.2147/TCRM.S107398 Text en © 2016 Moghaddam et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Moghaddam, Arash Graeser, Viola Westhauser, Fabian Dapunt, Ulrike Kamradt, Till Woerner, Stefan M Schmidmaier, Gerhard Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
title | Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
title_full | Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
title_fullStr | Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
title_full_unstemmed | Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
title_short | Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
title_sort | patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019425/ https://www.ncbi.nlm.nih.gov/pubmed/27660456 http://dx.doi.org/10.2147/TCRM.S107398 |
work_keys_str_mv | AT moghaddamarash patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse AT graeserviola patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse AT westhauserfabian patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse AT dapuntulrike patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse AT kamradttill patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse AT woernerstefanm patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse AT schmidmaiergerhard patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse |